Outlook for RNAi, 2007: siRNA and miRNA in Biology, Diagnostics and Therapeutics.LYON, France -- Reportlinker.com announces that a new market research report related to the worldwide biotechnology industry is now available to its catalogue. Outlook for RNAi, 2007: siRNA and miRNA in biology, diagnostics and therapeutics http://www.reportlinker.com/p054680/Outlook-RNAi.html RNAi-based screens have provided new opportunities for the discovery and validation of novel therapeutic targets in areas such as cancer and infectious diseases. Since 2005, enormous strides have also been made in the development of RNAi-based therapeutic products, bringing them significantly closer to the market. 'Outlook for RNAi 2007' is a new report which provides a detailed insight into the most effective use of this novel technology in the drug discovery and development process. It puts into context where RNAi technology is being used as a tool of choice within academia and the pharma industry for functional genomic studies, drug target discovery and mechanism of action studies. The development status RNAi based therapeutics is covered in detail, highlighting the key companies in the field, outlining their pipelines and describing the results of completed clinical trials. Understand how RNAi technology is being used to improve drug attrition rates and develop new therapeutic agents, and ensure that you are up-to-date with developments in this advancing field. Key findings * The RNAi market is a relatively immature with global sales of approximately $447 million in 2006. It is projected to reach $0.9 billion by 2010, a compound annual growth rate (CAGR CAGR See: Compound Annual Growth Rate ) of 19% between 2006-2010. * One of the main reasons for RNAi's popularity stems from its utility as a molecular biology tool enabling the in vivo functional analysis of thousands of genes. Recent advances in the field include the design of new libraries of RNAi effectors, delivery systems and read-out methods. * In 2005, delivering RNAi triggers was the biggest obstacle in creating effective RNAi-based therapies. Subsequently, research into new and effective delivery methods has taken place at a frantic pace, although there are still major issues to be addressed. The first human trials of a systemic RNAi-based therapeutic were initiated in 2007 by Quark Biotech. * In the last two years, a more thorough understanding of the mechanism of action and intracellular pathways of miRNA has developed. miRNA is now an alternative gene knock-down technology that is being applied in research and for therapeutic and diagnostic applications. Key questions answered * What will the growth of the RNAi market be over the next 5 years? * Who are the leading players in the RNAi market? * How are big pharma companies capitalizing on this technology through strategic alliances with specialized players? * Which areas of therapeutic interest are being explored with RNAi-based agents? * What are the Intellectual Property implications of RNAi research? * What challenges must be overcome for RNAi technology to yield commercially viable therapeutics and make a substantial improvement to drug-attrition rates? Key issues examined in this report * The value and breakdown of sub-sector performances of the RNAi market between 2006-2015. * The therapy areas, progress of clinical research, potential drug sales and patent position of companies at the forefront of RNAi-based therapeutics. * The relative strengths and weaknesses of different approaches to RNAi delivery and selectivity. * The key trends that are currently affecting the RNAi market such as the development of new reagents, availability of custom synthesized siRNA, development of RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic microarrays and their impact on the R&D process * The development of miRNA for diagnostic and therapeutic purposes. Table of content Executive Summary Introduction Design and Production of RNAi effectors RNAi Research and Applications Delivering RNAi therapeutics RNAi Therapeutics: Progress and the Future miRNA: diagnostics and therapeutics Regulatory issues and patents RNAi markets and trends Chapter 1 Introduction Summary Introduction DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. to RNA to protein - a primer Antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). technologies RNA interference Overview and significance RNAi's mechanism Post-transcriptional gene silencing (PGTS PGTS Precision Gunnery Training System ) by siRNA miRNA pathways Transcriptional gene silencing (TGS TGS Tokyo Game Show TGS Ticket-Granting Service TGS Ticket-granting Server TGS The Good Shepherd TGS Teen Girl Squad TGS The Gargoyles Saga TGS Texas Gourd Society TGS Tomato Growers Supply TGS Trinity Grammar School TGS Tomographic Gamma Scanner ) by siRNA Other non-coding RNAs Advantages and disadvantages of RNAi Report Outline Chapter 2 Design and Production of RNAi effectors Summary Introduction Design of RNAi effectors siRNA design algorithms Building silencing efficiency Avoiding off-target effects Chemical modification Avoiding immunostimulation Finding the right target sites miRNA mimics Production of RNAi effectors Chemical Synthesis siRNA pools Dicer-substrate siRNAs (DsiRNAs) Expression vectors Plasmid expression vectors Expression from a PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) product Viral expression vectors Conclusions Chapter 3 RNAi Research and Applications Summary Introduction Elucidating gene function High throughput loss-of-function screening with RNAi Choice of species and cell-line RNAi reagents Delivery method Screening paradigm and format Read-out methods Building pathways Investigating gene function in vivo Applications of RNAi in drug discovery and development Target discovery and validation Optimization of drug therapy and development of personalized medicine miRNA Research miRNA Databases and Algorithms Identifying miRNAs, their targets and function Isolation and enrichment of miRNA Detection and quantification of miRNA Functional analysis Conclusions Chapter 4 Delivering RNAi therapeutics Summary Introduction Direct organ delivery Stabilization of siRNAs Non-viral delivery methods Cholesterol and peptide conjugation conjugation, in genetics conjugation, in genetics: see recombination. conjugation, in grammar conjugation: see inflection. Liposomal delivery Conjugation with cell penetrating peptides Atelocollagen Targeted polymeric delivery Aptamer-siRNA complexes FAb-siRNA complexes MAb-siRNA complexes Targeted nanoparticle delivery methods Targeting with transferrin transferrin /trans·fer·rin/ (-fer´in) a glycoprotein mainly produced in the liver, binding and transporting iron, closely related to the apoferritin of the intestinal mucosa. trans·fer·rin n. Targeting with apatmers Targeting with RGD RGD Rijksgebouwendienst RGD Rat Genome Database RGD Registered Graphic Designer (Canada) RGD Arginine-Glycine-Aspartic Acid RGD Rapid Gas Decompression RGD Reacting Gas Dynamics RGD Range Gate Deception RGD Returned Goods Damaged peptide Delivering RNAi via Plasmid DNA Virosomes Viral delivery methods Conclusions Chapter 5 RNAi Therapeutics: Progress and the Future Summary Introduction siRNA Therapeutics: Analysis by Therapeutic Area Ocular Diseases Age-related Macular Degeneration Age-related macular degeneration (ARMD) Degeneration of the macula (the central part of the retina where the rods and cones are most dense) that leads to loss of central vision in people over 60. (AMD (Advanced Micro Devices, Inc., Sunnyvale, CA, www.amd.com) A major manufacturer of semiconductor devices including x86-compatible CPUs, embedded processors, flash memories, programmable logic devices and networking chips. ) Key RNAi players Diabetic Retinopathy Viral diseases Respiratory Syncytial Virus respiratory syncytial virus (sĭnsĭsh`əl): see cold, common. (RSV RSV respiratory syncytial virus; Rous sarcoma virus. RSV abbr. respiratory syncytial virus RSV 1 Respiratory syncytial virus, see there 2 Rous sarcoma virus, see there ) Key RNAi Players HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. Key RNAi players Hepatitis C Virus
abbr. hepatitis C virus HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. ) Key RNAi players Hepatitis B Virus (HBV HBV hepatitis B virus. HBV abbr. hepatitis B virus ) Key RNAi players Pandemic Flu Key RNAi players SARS Key RNAi players Herpes Simplex Virus Herpes simplex virus A virus that can cause fever and blistering on the skin, mucous membranes, or genitalia. Mentioned in: Conjunctivitis herpes simplex virus (HSV (Hue Saturation Value) A color space similar to HSB. See HSB. HSV - hue, saturation, value ) Other viral diseases Respiratory diseases Asthma and Chronic Obstructive Pulmonary Disease chronic obstructive pulmonary disease n. Abbr. COPD A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced. (COPD COPD chronic obstructive pulmonary disease. COPD abbr. chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) ) Key RNAi Players Cystic fibrosis (CF) Key RNAi players Neurological diseases Oncology Angiogenesis Key RNAi players Oncogenes oncogenes 1. genes carried by tumor viruses that are directly and solely responsible for the neoplastic transformation of host cells. Many oncogenes function after integration into the DNA of the host cell and some up-regulate normal downstream host cell genes to cause neoplasia. Key RNAi players Cardiovascular disease Key RNAi players Metabolic disorders Diabetes and Obesity Key RNAi players Dermatology Hair Removal Key RNAi players Pachyonychia congenita and related disorders Key RNAi Players Acute renal failure acute renal failure Acute kidney failure Nephrology An abrupt decline in renal function, triggered by various processes–eg, sepsis, shock, trauma, kidney stones, drug toxicity-aspirin, lithium, substances of abuse, toxins, iodinated radiocontrast. Key RNAi players Acute hearing loss/ pressure sores ototoxicity Ototoxicity Definition Ototoxicity is damage to the hearing or balance functions of the ear by drugs or chemicals. Description Ototoxicity is drug or chemical damage to the inner ear. Key RNAi players Inflammatory Diseases Key RNAi players Conclusions Chapter 6 miRNA: diagnostics and therapeutics Summary Introduction miRNA as a diagnostic tool Companies developing miRNA-based diagnostics Rosetta Genomics Cepheid Stratagene miRNA-based therapeutics Companies developing miRNA-based therapeutics Alnylam Pharmaceuticals Asuragen Inc Santaris Sirna Conclusions Chapter 7 Regulatory issues and patents Summary Introduction Patents in RNAi Seminal patents in RNAi Alnylam Sirna Chemical modifications DNA directed RNAi Patents for specific RNAi targets The future - more patent litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. ? MicroRNA Tuschl III patents Zamore and other patents Regulatory considerations for RNAi therapies Conclusions Chapter 8 RNAi markets and trends Summary Introduction The RNAi market Market size and future trends RNAi suppliers: synthesis and reagents Alliances with big pharma for RNAi in R&D Delivery of RNAi therapeutics RNAi-based therapeutics Big pharma alliances for RNAi-based therapeutics miRNA-based diagnostics Conclusion More market research reports? Go to http://www.reportlinker.com http://www.reportlinker.com/Rss/en01234/biotech-free-market-resear ch-reports.xml http://www.reportlinker.com/Rss/en01237/biotechnology-free-market- research-reports.xml http://www.reportlinker.com/Rss/en012605/biotechnology-instrumenta tion-free-market-research-reports.xml http://www.reportlinker.com/Rss/en015656/biotechnology-patent-free -market-research-reports.xml http://www.reportlinker.com/Rss/en012624/biotechnology-patents-fre e-market-research-reports.xml http://www.reportlinker.com/Rss/en012615/biotech-drug-discovery-pr ocess-free-market-research-reports.xml (Due to their length, these URLs may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion